Patent application number | Description | Published |
20120277245 | Method of Increasing Intratumoral pHe and Reducing Acid-Mediated Invasion - A method of treating cancer or inhibiting metastasis in a subject by increasing intratumoral extracellular pH is presented. The method includes administering to the subject a therapeutically effective amount of a buffer having a pKa greater than 6.1. In an advantageous embodiment the pKa of the buffer is about 7.0. Examples of buffers for increasing extracellular pH include NaHCO | 11-01-2012 |
20130129619 | Molecular Imaging of Cancer Cells In Vivo - Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods. | 05-23-2013 |
20140045796 | TRANSIENT HYPOXIA INDUCERS AND THEIR USE - The identification of pO | 02-13-2014 |
20140105827 | METHOD OF SCREENING FOR COLON CANCER USING BIOMARKERS - The present invention relates to biomarkers for colon cancers, specifically adenomas and adenocarcinomas in the GI tract. The inventors have discovered that the expression and/or overexpression of biomarkers such as CLDN1, GPR56, GRM8, LY6G6D, TLR4 and SLCO1B3 are indicative of adenomas and adenocarcinomas. A method of detecting colon cancer using targeted molecular imaging agents is also presented. | 04-17-2014 |
20140112873 | MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE - The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell. | 04-24-2014 |
20140161725 | Molecular Imaging of Cancer Cells In Vivo - Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods. | 06-12-2014 |
20150356730 | QUANTITATIVE PREDICTORS OF TUMOR SEVERITY - Disclosed are methods for quantitatively predicting the severity of a tumor in a subject. In some embodiments, the methods further comprise selecting a course of therapy for the subject. In some embodiments, the tumor comprises is non-small cell lung cancer. | 12-10-2015 |
20160051704 | MOLECULAR IMAGING PROBES FOR LUNG CANCER INTRAOPERATIVE GUIDANCE - Molecular probes directed to the delta opioid receptor and associated methods of use as non-invasive diagnostics for lung cancer are presented. The molecular probes generally consist of a ligand (Dmt-Tic) that is conjugated to a detection moiety such as a fluorescent dye or a radionuclide by a linker molecule. Once the probe is administered, it may be detected by a molecular imaging device to locate tumors for treatment or removal. Also presented are novel markers for lung cancer including, but not limited to, CA9, CA12, CTAG2, CXorf61, DSG3, FAT2, KISS1R, GPR87, LYPD3, OPRD1, SLC7A11 and TMPRSS4. Probes may be developed that can target these cell surface markers. | 02-25-2016 |